• Jing Xie, Xueying Li, Yang Chen, Ming Chen, Nan Mao, and Junming Fan.
• Hospital of Chengdu University of Traditional Chinese Medicine.
• Medicine (Baltimore). 2020 Nov 13; 99 (46): e22566.

BackgroundSecondary hyperparathyroidism (SHPT) have been associated with poor health outcomes in hemodialysis patients. The cinacalcet has popularized in clinic which has efficacy but more adverse events; the novel oral calcimimetic agents evocalcet has appeared in recent years. However, it is currently unknown whether evocalcet produces more beneficial effects and fewer adverse events in patients with SHPT. The aim of this systematic review is to estimate the safety and efficacy of evocacelt.MethodsOnly randomized controlled trials (RCT) will be included in MEDLINE, EMBASE, the Cochrane Register of Controlled Trials, and PUBMED from July 2010 to July 2020. Two reviewers will screen, select studies, extract data, and assess quality independently. The methodological quality including the risk of bias of the included studies will be evaluated using a modified assessment form, which is based on Cochrane assessment tool. Review Manager 5.3 software will be used for heterogeneity assessment, generating funnel-plots, data synthesis, subgroup analysis, and sensitivity analysis. We will use GRADE system to evaluate the quality of our evidence.ResultsWe will provide some more practical and targeted results investigating the effect and safety of evocalcet for SHPT on hemodialysis in the current meta-analysis.ConclusionThe stronger evidence about evocalcet effect and safety will be provided for clinicians and policymakers.Ethics And DisseminationEthical approval will be unnecessary because the data being included in this systematic review come from published literature and there will be no concerns regarding privacy. Findings of this research will be disseminated in a peer-reviewed journal or conference presentations.Osf Registration NumberDOI 10.17605/OSF.IO/N59RB.

19 keywords...

hide…